HealthcareServices

Biosimilar Testing Services Industry Overview 2025: Growth Projections and Market Trends

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Biosimilar Testing Services Market Covering 2025–2034?

The biosimilar testing services market has demonstrated substantial growth in recent years. Its size is expected to expand from $1.62 billion in 2024 to $1.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.3%. This historical development can be linked to factors such as the rising demand for biologics, the increasing approval of biosimilars, the growing prevalence of chronic diseases, a heightened demand for personalized medicine, and the expansion of clinical trial activities.

The biosimilar testing services market is projected to experience significant expansion in the coming years. It is anticipated to reach a valuation of $2.99 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 13.0%. This anticipated growth during the forecast period stems from factors such as the rising acceptance of biosimilars, an escalating need for economical treatment options, a surge in the requirement for affordable biologic therapies, heightened confidence in the effectiveness and safety of biosimilars, and an expanding call for tailored testing solutions. Key trends expected within this period encompass progress in analytical testing technologies, ongoing breakthroughs in bioassay development, the increasing integration of high-throughput testing platforms, intensified research and development efforts in biosimilar analytics, and the incorporation of artificial intelligence for data analysis.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27225&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Biosimilar Testing Services Industry?

The increasing occurrence of autoimmune conditions is anticipated to drive the expansion of the biosimilar testing services market moving ahead. These conditions involve the body’s immune system erroneously targeting its own healthy cells and tissues, resulting in inflammation and harm to tissues. This rise in autoimmune disease prevalence stems from a heightened demand for potent biologic therapies capable of managing persistent symptoms, decreasing flare-ups, and enhancing patient outcomes over time. Biosimilar testing services contribute to autoimmune disease treatment by verifying that biosimilars are secure, efficacious, and equivalent to their original biologic counterparts, thereby facilitating the availability of economical and accessible treatment choices. As an illustration, in June 2024, the Australian Institute of Health and Welfare, a government entity located in Australia, reported that approximately 514,000 individuals (2.0%) in Australia had rheumatoid arthritis in 2022, affecting 2.5% of females and 1.6% of males. Consequently, the expanding incidence of autoimmune diseases is fueling the development of the biosimilar testing services market.

What Are The Major Segments Identified In The Biosimilar Testing Services Market?

The biosimilar testing services market covered in this report is segmented

1) By Service Type: Analytical Testing, Bioanalytical Testing, Stability Testing, Method Development And Validation, Other Service Types

2) By Technology: Cell-Based Assays, Chromatography Techniques, Mass Spectrometry, Bioassays

3) By Molecule Type: Monoclonal Antibodies, Recombinant Hormones, Insulin, Interferons, Enzymes, Other Molecule Types

4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Government Agencies

Subsegments:

1) By Analytical Testing: Protein Characterization, Impurity Profiling, Potency Testing, Glycosylation Analysis, Structural Analysis

2) By Bioanalytical Testing: Pharmacokinetics Analysis, Immunogenicity Testing, Biomarker Analysis, Drug Concentration Measurement, Toxicokinetics Testing

3) By Stability Testing: Long-Term Stability Testing, Accelerated Stability Testing, Stress Testing, Photostability Testing, Temperature Cycling Studies

4) By Method Development And Validation: Analytical Method Development, Bioanalytical Method Development, Method Validation, Process Validation, Assay Development

5) By Other Service Types: Immunogenicity Assessment, Formulation Development, Microbial Testing, Release Testing, Regulatory Consulting

Which Key Trends Are Expected To Influence The Biosimilar Testing Services Market In The Coming Years?

Companies operating within the biosimilar testing services market are increasingly expanding their facilities to integrate new technologies or advanced capabilities, aiming to improve productivity and market competitiveness. This facility expansion entails the enlargement or enhancement of existing physical spaces or infrastructure to accommodate greater operational requirements or support future growth. For example, in October 2023, Tanvex BioPharma USA Inc., a US-based biotechnology firm, introduced Tanvex CDMO, a modern contract development and manufacturing organization located in San Diego. This organization offers comprehensive biologics development and manufacturing services, encompassing cell line development, process optimization, analytical testing, and regulatory support. The primary goal of this new facility is to accelerate the development of biopharmaceutical products from their initial concept to commercial scale, utilizing advanced technologies and skilled teams to deliver innovative and life-altering biologics to patients globally.

Which Leading Companies Dominate The Biosimilar Testing Services Market Share?

Major companies operating in the biosimilar testing services market are Thermo Fisher Scientific Inc., IQVIA Laboratories, Laboratory Corporation of America Holdings, Fresenius SE & Co. KGaA, Eurofins Scientific SE, Intas Pharmaceuticals Ltd., SGS Société Générale de Surveillance SA, WuXi AppTec Co. Ltd., Intertek Group plc, Samsung Biologics Co. Ltd., Celltrion Inc., Almac Group Limited, Syngene International Limited, Shanghai Medicilon Inc., Kymos Group S.L., Pacific BioLabs Inc., Profacgen Inc., ExcellGene SA, BioPharmaSpec Ltd., and Sartorius Stedim Biotech Group.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biosimilar-testing-services-global-market-report

What Regional Growth Trends Are Shaping The Biosimilar Testing Services Market Outlook?

North America was the largest region in the biosimilar testing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar testing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Biosimilar Testing Services Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27225&type=smp

Browse Through More Reports Similar to the Global Biosimilar Testing Services Market 2025, By The Business Research Company

Cold Insulation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-insulation-global-market-report

Insulation Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulation-products-global-market-report

Aircraft Insulation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aircraft-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795